Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
http://www.reportbuyer.com/pharma_healthcare/therapeutic/chronic_obstructive_pulmonary_disorder_copd_kol_insight_consensus_outlook.html
The prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, its impact on the wider health economy is significant and there remains considerable unmet clinical need. Valued at US$10 billion and with a 5 year CAGR of 7.1% this high growth sector is set for radical change as new products and combinations are introduced changing both the treatment and competitive landscapes.
The cosy carve up of the market between Pfizer's Spiriva (tiotropium) and GSK's Advair/Serotide (fluticasone propionate/salmeterol), which currently account for 75% of sales globally, will be challenged by new entrants that provide better patient adherence, improve lung function, tackle inflammation and reduce exacerbations of the disease.
Why is COPD causing such excitement?
There is considerable industry and investor excitement about COPD treatment developments. Which of the new products will find favour with clinicians? What regulatory hurdles must they overcome? Do they offer a real clinical improvement over current therapies? Stripping away the hype and harnessing the real world insights from leading US and European KOL's, this Therapy Trends analysis critically examines the products and research and exposes the real potential. For example:
A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers
For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative COPD market forecast look no further than FirstWord's Therapy Trends: COPD. This comprehensive FirstWord research is available in two comprehensive modules:
KOL Insight
KOL Insight Report
Event Bulletins
Consensus Outlook
Consensus Report
Interactive Analytics File
Key Benefits
Therapy Trends KOL Insight: COPD analyses the current and predicted key issues, current products and late-stage pipeline products. The report gives you qualitative, inside information from exclusive FirstWord interviews with 12 key opinion leaders (KOLs) through the following:
Key Report Features and Benefits
All current therapeutic approaches covered
Expert Opinion for Real World Insights
The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in COPD in the US and
Europe. Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed.
Key Quotes from the Report
"I think what will be in the best interest of the COPD population is that the LABA/LAMA combination becomes accepted as foundation therapy for anyone with more than mild COPD. Patients who have moderate COPD would benefit most from being on a LABA/LAMA combination." Professor Christopher Cooper (US)
"I think we are looking at a major shift. The name of the game here is maximum bronchodilation. We need to provide the maximum bronchodilation as possible. We are working with two different mechanisms of action; so two mechanisms that complement each other so they are not excluding each other, so that they compliment. And that's the market; the way the market is looking and the way the market is shaping up. Everybody is like, 'well, this is probably the way for us to go." Dr Antonio Anzueto (US)
"We desperately need new anti-inflammatory agents. That's what will take us to the next level. And this almost lemming rush that pharmaceutical companies have of doing the same thing as somebody else does so you can be the first to the market with it." Professor Byron Thomashow (US)
"The problem with Relvar/Breo is when you look at the data when they compared their new drug with their old drug there are no convincing differences. From my point of view it's a once-daily Advair. That's all it is." Professor Claus Vogelmeier (Europe)
Consensus Outlook
Use this detailed report and powerful interactive Excel spread sheet to compare and contrast companies and products now and in the future. Therapy Trends Consensus Outlook: COPD includes the following comprehensive resources:
Report features:
Use Consensus Outlook to
Analysts compared
Content Highlights and Products Covered
Reasons to Buy this Report
KOL, Analysts, Products and Companies
At a glance listings of those who contributed and the rich and varied sources accessed to produce this major analysis of the COPD market and its prospects.
Key Opinion Leaders
Analysts
Products & Companies Covered
Ongoing Benefits
Continually Updated in Response to Market Developments
The world of pharma is ever changing and executives must always be up- to-date with the latest developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends updated offers real commercial advantage. Consider the benefits:
Consider the benefits:
Whatever happens in the market you'll always be able to assess the impact with FirstWord Therapy Trends
Unrivalled Sources Ensure Complete Coverage
Our unique disease selection matrix pinpoints those disease sectors of the highest commercial potential, and draws information from multiple novel and expert sources, including:
Contents Consensus Outlook
1.Analysis Highlights
2.Research Methodology
3.Chronic Obstructive Pulmonary Disease Marketplace
4.Key Chronic Obstructive Pulmonary Disease Developers
5.Chronic Obstructive Pulmonary Disease Class Dynamics
6.Spiriva (tiotropium; Boehringer Ingelheim/Pfizer) forecast
7.Eklira/Tudorza (aclidinium; Almirall/Forest) forecast
8.Seebri (glycopyrronium; Novartis) forecast
9.Ultibro (glycopyrronium/indacaterol; Novartis) forecast
10.Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline) forecast
11.Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline) forecast
12.Symbicort (budesonide/formoterol; AstraZeneca) forecast
13.Arcapta/Onbrez (indacaterol; Novartis) forecast
14.Daliresp/Daxas (roflumilast; Takeda/Forest) forecast
15.Anoro (umeclidinium/vilanterol; GlaxoSmithKline) forecast
16.Aclidinium/formoterol (Almirall/Forest) forecast
KOL insight
1.Executive summary
2.Introduction
3.Methodology
4.Current chronic obstructive pulmonary disease marketplace
5.Chronic obstructive pulmonary disease overview
5.1.Epidemiology
5.2.Aetiology
5.3.Risk factors
5.4.Symptoms
5.5.Diagnosis
5.6.Chronic obstructive pulmonary disease treatments
5.6.1.COPD treatment landscape
5.6.2.COPD market definition
5.6.3.Current market overview
5.7.Formulary coverage of chronic obstructive pulmonary disease drugs
6.Current therapies
6.1.Key trials with approved therapies
6.1.2.Spiriva (UPLIFT); FEV1 decline and exacerbations
6.1.3.Spiriva (POET-COPD): LAMA v LABA, exacerbations
6.1.4.Advair/Seretide (TORCH): mortality
6.1.5.Seretide (TRISTAN): lung function and exacerbations
6.1.6.Spiriva versus Seretide (INSPIRE): exacerbations
6.1.7.Triple therapy (OPTIMAL): ICS/LABA plus LAMA
6.2.Long-Acting Muscarinic Antagonists (LAMAs)
6.2.1.Spiriva (tiotropium; Boehringer Ingelheim/Pfizer)
6.2.2.Eklira/Tudorza (aclidinium; Almirall/Forest)
6.2.3.Seebri (glycopyrronium; Novartis)
6.3.Fixed-dose Long-Acting Muscarinic Antagonist/Long-Acting Beta2 Agonist combinations
6.3.1.Ultibro (glycopyrronium/indacaterol; Novartis)
6.3.2.Anoro (umeclidinium/vilanterol; GlaxoSmithKline)
6.4.Fixed-dose Inhaled Corticosteroid/Long-Acting Beta2 Agonist (ICS/LABA) combinations
6.4.1.Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline)
6.4.2.Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline)
6.4.3.Symbicort (budesonide/formoterol; AstraZeneca)
6.5.Long-Acting Beta2 Agonists (LABAs)
6.5.1.Arcapta/Onbrez (indacaterol; Novartis)
6.5.2.Striverdi (olodaterol; Boehringer Ingelheim)
6.6.Phosphodiesterase-IV (PDE-IV) inhibitors
6.6.1.Daliresp/Daxas (roflumilast; Takeda/Forest)
7.Pipeline therapies
7.1.Fixed-dose Long-Acting Muscarinic Antagonist/Long-Acting Beta2 Agonist (LAMA/LABA) 7.2.combinations
7.2.1.Tiotropium/olodaterol (Boehringer Ingelheim)
7.2.2.Aclidinium/formoterol (Almirall/Forest)
7.2.3.Glycopyrronium/formoterol (AstraZeneca/Pearl Therapeutics)
7.3.Fixed-dose triple ICS/LAMA/LABA combinations
7.3.1.Chiesi's triple fixed-dose combination
7.3.2.GlaxoSmithKline's Ellipta device: a platform for triple therapies
7.4.Muscarinic antagonists/beta2 agonists (MABAs)
7.5.Novel anti-inflammatories and anti-oxidants
8.Treatment focus
8.1.Unmet needs in chronic obstructive pulmonary disease
8.1.1.Unmet need 1: Novel agents that modify disease progression and/or reduce exacerbations
8.1.2.Unmet need 2: Early detection of COPD
8.1.3.Unmet need 3: Improving patient drug adherence
8.1.4.Unmet need 4: Confirming COPD diagnosis
8.1.5.Unmet need 5: Understanding the mechanism of action of COPD drugs
8.2.Current chronic obstructive pulmonary disease treatment algorithm
8.2.1.GOLD guidelines
8.2.2.NICE guidelines (England and Wales)
8.3.Device is not a deciding factor in selecting treatments
8.4.Current chronic obstructive pulmonary disease treatment practice
8.4.1.Treatment practice: US
8.4.2.Treatment practice: England
8.4.3.Treatment practice: Spain, France, Italy
8.4.4.Prescribing point 1: ICS are widely used to treat COPD
8.4.5.Prescribing point 2: Free-dose ICS are not approved for COPD in the US or EU
8.4.6.Prescribing point 3: FDA's heightened risk attitude towards LABAs
8.4.7.Prescribing point 4: EMA and FDA have approved different doses
9.1.Future chronic obstructive pulmonary disease treatment algorithm
9.2.LAMA/LABAs provide maximum bronchodilation
9.3.LAMA/LABAs introduce a drug sequencing issue
9.4.ICS withdrawal is a key resistor to LAMA/LABA uptake
9.5.Commercial success of Combivent supports LAMA/LABA US uptake
9.6.Comparative data with ICS/LABAs could accelerate clinical adoption of LAMA/LABAs
10.Future treatment landscape
10.1.Smoking cessation vaccines
10.2.Novel vaccines and anti-virals to reduce exacerbations
10.3.Novel endpoints
10.4.Generic drugs
11.Appendix
11.1indication specific sales
11.2.KOL biographies
11.3.KOLs from US
11.4.KOLs from Europe
Read the full report:
Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
http://www.reportbuyer.com/pharma_healthcare/therapeutic/chronic_obstructive_pulmonary_disorder_copd_kol_insight_consensus_outlook.html
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article